Hello. Thank you for writing to us Humira Or adalimumab is a human monoclonal antibody that targets the inflammatory pathway that is involved in psoriasis. Adalimumab is generally administered every 2 weeks. Though it is very effective in controlling and improving psoriasis scores but it can be associated with serious side effects like re-activation of Tuberculosis, hepatitis and increased risk of opportunistic infections (bacterial, viral and fungal). Therefore, attempt should always be made to taper it off once psoriasis is under good control. I think your physician did try to do the same. However, since psoriasis is recurrent disease and can recur even while the patient is on adalimumab. This is known as secondary failure i.e recurrence in spite of being on treatment. In this scenario I would suggest reverting back to once weekly dose for 2 weeks and then maintain with once every 2 weeks doses. I suggest that you talk to your doctor for the needful. Regards